3 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
To identify the influence of two different biocompatible-coated extracorporeal circuits on the perfused boundary region of the sublingual microvasculature as measured by the GlycoCheck Sidestream Darkfield Imaging camera.
Approved WMOCompleted
The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.